Merck to Acquire Acceleron for ~$11.5B
Shots:
- Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected to close in Q4’21
- The acquisition will strengthen Merck’s cardiovascular pipeline. Acceleron’s sotatercept is currently in P-III trials & has the potential to improve short-term & long-term clinical outcomes in patients with PAH
- In 2011- Acceleron has entered into a collaboration with BMS to develop and commercialize Reblozyl. The therapy has been approved in the US- EU- Canada- and Australia for the treatment of anemia in rare blood disorders
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com